This Week in BMC Cancer

Premium

In BMC Cancer this week, researchers in Brazil report on the efficacy of bevacizumab when added to first-line chemotherapy in the treatment of advanced colorectal cancer. The team conducted a meta-analysis of clinical trials using bevacizumab in first-line metastatic colorectal cancer — six trials and 3,060 patients in total. They found that there was an advantage to using bevacizumab for overall survival and progression-free survival.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.